{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:45:30Z","timestamp":1766760330269,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bone.2019.115084","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:53:43Z","timestamp":1571662423000},"page":"115084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Combination therapy in the Col1a2G610C mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGF\u03b2 signaling on trabecular bone but not on cortical bone"],"prefix":"10.1016","volume":"131","author":[{"given":"Shannon","family":"Kaupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan J.","family":"Horan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Robling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-3449","authenticated-orcid":false,"given":"Matthew L.","family":"Warman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.115084_bib0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2019.115084_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00223-015-9996-2","article-title":"The role of collagen organization on the properties of bone","volume":"97","author":"Garnero","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.115084_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajmg.a.37377","article-title":"Quality of life in osteogenesis imperfecta: a mixed-methods systematic review","volume":"170A","author":"Dahan-Oliel","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2019.115084_bib0020","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s11136-016-1247-0","article-title":"The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review","volume":"25","author":"Tsimicalis","year":"2016","journal-title":"Qual. Life Res."},{"issue":"12","key":"10.1016\/j.bone.2019.115084_bib0025","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115084_bib0030","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.bone.2019.115084_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1620\/tjem.242.115","article-title":"Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta","volume":"242","author":"Uehara","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.bone.2019.115084_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bone.2019.115084_bib0045","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"5","key":"10.1016\/j.bone.2019.115084_bib0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2019.115084_bib0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bone.2019.115084_bib0060","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"20","key":"10.1016\/j.bone.2019.115084_bib0065","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bone.2019.115084_bib0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","article-title":"The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations","volume":"82","author":"Balemans","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2019.115084_bib0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bone.2019.115084_bib0080","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.115084_bib0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0090","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.115084_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0100","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.115084_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2019.115084_bib0110","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0115","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2388","article-title":"Lrp5 functions in bone to regulate bone mass","volume":"17","author":"Cui","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2019.115084_bib0120","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bone.2016.06.005","article-title":"Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+\/mov13) mouse model of type I Osteogenesis Imperfecta","volume":"90","author":"Jacobsen","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S8756-3282(03)00158-3","article-title":"The T869C TGF beta polymorphism is associated with fracture, bone mineral density, and calcaneal quantitative ultrasound in elderly women","volume":"33","author":"Dick","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002230020024","article-title":"Association of transforming growth factor-beta1 (TGFbeta1) T29 --> C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal German women","volume":"69","author":"Hinke","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.115084_bib0140","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1242\/dev.126.19.4267","article-title":"Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass","volume":"126","author":"Filvaroff","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.bone.2019.115084_bib0145","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.139","article-title":"Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo","volume":"25","author":"Edwards","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0150","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.celrep.2017.10.115","article-title":"Osteocyte-intrinsic TGF-beta signaling regulates bone quality through perilacunar\/canalicular remodeling","volume":"21","author":"Dole","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bone.2019.115084_bib0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2019.115084_bib0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbmr.3617","article-title":"Effect of Anti-TGF-beta treatment in a mouse model of severe osteogenesis imperfecta","volume":"34","author":"Tauer","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"52","key":"10.1016\/j.bone.2019.115084_bib0170","first-page":"54","article-title":"Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT)","volume":"29","author":"Truett","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.bone.2019.115084_bib0175","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","author":"Sawakami","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bone.2019.115084_bib0180","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0185","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2019.115084_bib0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","article-title":"Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","volume":"91","author":"Nyman","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1532-5415.1982.tb03698.x","article-title":"Combination therapy for osteoporosis with estrogen, fluoride, and calcium","volume":"30","author":"Aloia","year":"1982","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.bone.2019.115084_bib0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115084_bib0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015187","article-title":"Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials","volume":"8","author":"Lou","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2019.115084_bib0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009534","article-title":"Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: a meta-analysis","volume":"96","author":"Lou","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2019.115084_bib0215","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1210\/en.2017-00355","article-title":"Improving combination osteoporosis therapy in a preclinical model of heightened osteoanabolism","volume":"158","author":"Shao","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2019.115084_bib0220","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2019.115084_bib0225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0230","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jc.2003-030198","article-title":"Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis","volume":"89","author":"Evio","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115084_bib0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2019.115084_bib0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0245","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/jbmr.3421","article-title":"Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl\/+ osteogenesis imperfecta mouse model","volume":"33","author":"Olvera","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0255","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115084_bib0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115084_bib0270","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(-\/-) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115084_bib0275","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219303771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219303771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:47:24Z","timestamp":1757612844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219303771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":55,"alternative-id":["S8756328219303771"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115084","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in the Col1a2G610C mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGF\u03b2 signaling on trabecular bone but not on cortical bone","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115084"}}